Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06435260

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

To Explore the Efficacy of Hypofractionated Radiotherapy Followed by AG Regimen Chemotherapy Plus Camrelizumab Immunotherapy as Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer

Sponsor: Hebei Medical University Fourth Hospital

Conditions Pancreatic Cancer

Interventions Camrelizumab+chemotherapy hypofractionated radiotherapy

Updated 5 times since 2024 Last updated: Jun 25, 2025 Started: Aug 1, 2024 Primary completion: Jun 1, 2025 Completion: Jun 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06435260, this PHASE2 trial focuses on Pancreatic Cancer and remains actively recruiting participants. Sponsored by Hebei Medical University Fourth Hospital, it has been updated 5 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Jul 2025 — Present [monthly]

Recruiting PHASE2
Apr 2025 — Jul 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hebei Medical University Fourth Hospital

Data source: Hebei Medical University Fourth Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shijiazhuang, China